These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 10588170)
1. Therapeutic approach to the patient with irritable bowel syndrome. Camilleri M Am J Med; 1999 Nov; 107(5A):27S-32S. PubMed ID: 10588170 [TBL] [Abstract][Full Text] [Related]
2. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Camilleri M Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():48-53. PubMed ID: 10429740 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic therapy for the irritable bowel syndrome. Talley NJ Am J Gastroenterol; 2003 Apr; 98(4):750-8. PubMed ID: 12738451 [TBL] [Abstract][Full Text] [Related]
5. Irritable bowel syndrome: update on pathogenesis and management. Alaradi O; Barkin JS Med Princ Pract; 2002; 11(1):2-17. PubMed ID: 12116690 [TBL] [Abstract][Full Text] [Related]
6. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. De Ponti F; Tonini M Drugs; 2001; 61(3):317-32. PubMed ID: 11293643 [TBL] [Abstract][Full Text] [Related]
7. [Guidelines for the treatment of irritable bowel syndrome]. Kwon JG; Park KS; Park JH; Park JM; Park CH; Lee KJ; Park HJ; Rhee JC; Korean J Gastroenterol; 2011 Feb; 57(2):82-99. PubMed ID: 21350320 [TBL] [Abstract][Full Text] [Related]
8. Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS. Lacy BE Neurogastroenterol Motil; 2016 Jan; 28(1):26-35. PubMed ID: 26690872 [TBL] [Abstract][Full Text] [Related]
9. Current gut-directed therapies for irritable bowel syndrome. Chang HY; Kelly EC; Lembo AJ Curr Treat Options Gastroenterol; 2006 Jul; 9(4):314-23. PubMed ID: 16836950 [TBL] [Abstract][Full Text] [Related]
10. Drug treatment options for irritable bowel syndrome: managing for success. Dunphy RC; Verne GN Drugs Aging; 2001; 18(3):201-11. PubMed ID: 11302287 [TBL] [Abstract][Full Text] [Related]
11. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Scarpignato C; Pelosini I Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210 [TBL] [Abstract][Full Text] [Related]
12. Irritable bowel syndrome: new pharmaceutical approaches to treatment. Farthing MJ Baillieres Best Pract Res Clin Gastroenterol; 1999 Oct; 13(3):461-71. PubMed ID: 10580922 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic and therapeutic strategies in the irritable bowel syndrome. Cremonini F; Talley NJ Minerva Med; 2004 Oct; 95(5):427-41. PubMed ID: 15467518 [TBL] [Abstract][Full Text] [Related]
14. Management of the irritable bowel syndrome. Camilleri M Gastroenterology; 2001 Feb; 120(3):652-68. PubMed ID: 11179242 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. Mearin F Digestion; 2006; 73 Suppl 1():28-37. PubMed ID: 16498250 [TBL] [Abstract][Full Text] [Related]
16. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Cash BD; Lacy BE; Rao T; Earnest DL Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529 [TBL] [Abstract][Full Text] [Related]
17. Irritable bowel syndrome: evaluation and treatment. Somers SC; Lembo A Gastroenterol Clin North Am; 2003 Jun; 32(2):507-29. PubMed ID: 12858604 [TBL] [Abstract][Full Text] [Related]
18. Drug therapy options for patients with irritable bowel syndrome. Talley NJ Am J Manag Care; 2001 Jul; 7(8 Suppl):S261-7. PubMed ID: 11474911 [TBL] [Abstract][Full Text] [Related]
19. New and emerging treatments for irritable bowel syndrome and functional dyspepsia. Talley NJ Expert Opin Emerg Drugs; 2002 May; 7(1):91-8. PubMed ID: 15989538 [TBL] [Abstract][Full Text] [Related]
20. Update in the therapeutic management of irritable bowel syndrome. Villanueva A; Domínguez-Muñoz JE; Mearin F Dig Dis; 2001; 19(3):244-50. PubMed ID: 11752844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]